- 全部删除
- 您的购物车当前为空
HDAC-IN-79(compound 4)是一种口服活性的黄嘌呤氧化酶-HDAC双重抑制剂,其对Xanthine oxidase和多种HDAC亚型具有高度选择性抑制效果(Xanthine oxidase: IC50=6.6 nM; HDAC1: IC50=134 nM; HDAC2: IC50=284 nM; HDAC3: IC50=173 nM; HDAC6: IC50=1.32 nM)。此化合物在体内显示出优异的抗高尿酸血症和抗肿瘤活性。在白血病细胞HL60中,HDAC-IN-79展现出最强的细胞生长抑制作用(IC50=0.706 μM),能有效诱导细胞凋亡(apoptosis)和自噬(autophagy),并调控与HDAC抑制相关的生物标志物表达。
HDAC-IN-79(compound 4)是一种口服活性的黄嘌呤氧化酶-HDAC双重抑制剂,其对Xanthine oxidase和多种HDAC亚型具有高度选择性抑制效果(Xanthine oxidase: IC50=6.6 nM; HDAC1: IC50=134 nM; HDAC2: IC50=284 nM; HDAC3: IC50=173 nM; HDAC6: IC50=1.32 nM)。此化合物在体内显示出优异的抗高尿酸血症和抗肿瘤活性。在白血病细胞HL60中,HDAC-IN-79展现出最强的细胞生长抑制作用(IC50=0.706 μM),能有效诱导细胞凋亡(apoptosis)和自噬(autophagy),并调控与HDAC抑制相关的生物标志物表达。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 期货 | |
50 mg | 询价 | 期货 |
产品描述 | HDAC-IN-79 (compound 4) is an orally active dual inhibitor of xanthine oxidase and HDAC, exhibiting potent anti-hyperuricemia and antitumor activities in vivo (Xanthine oxidase: IC50=6.6 nM; HDAC1: IC50=134 nM; HDAC2: IC50=284 nM; HDAC3: IC50=173 nM; HDAC6: IC50=1.32 nM). Among leukemia cells, it is most effective in inhibiting the growth of HL60 cells (IC50=0.706 μM) and induces both apoptosis and autophagy. HDAC-IN-79 also modulates the expression levels of biomarkers associated with intracellular HDAC inhibition. |
靶点活性 | HDAC1:134 nM, HDAC2:284 nM, HDAC3:173 nM, HDAC6:1.32 nM |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容